Koers Sawai Pharmaceutical Co., Ltd. Japan Exchange
Aandelen
4555
JP3323050009
Farmaceutische producten
Omzet 2024 * | 194 mld. 1,22 mld. 1,14 mld. | Omzet 2025 * | 203 mld. 1,28 mld. 1,2 mld. | Marktkapitalisatie | 261 mld. 1,65 mld. 1,54 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 19,79 mld. 125 mln. 117 mln. | Nettowinst (verlies) 2025 * | 19,91 mld. 126 mln. 118 mln. | EV/omzet 2024 * | 1,53 x |
Nettoschuld 2024 * | 34,69 mld. 219 mln. 205 mln. | Nettoschuld 2025 * | 39,72 mld. 251 mln. 235 mln. | EV/omzet 2025 * | 1,48 x |
K/w-verhouding 2024 * |
13,2
x | K/w-verhouding 2025 * |
13,1
x | Werknemers | 3.393 |
Dividendrendement 2024 * |
2,18% | Dividendrendement 2025 * |
2,31% | Vrij verhandelbaar | 0% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mitsuo Sawai
CEO | Chief Executive Officer | 67 | 01-04-21 |
President | 66 | 01-04-21 | |
Toru Terashima
BRD | Director/Board Member | 64 | 01-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitsuo Sawai
CEO | Chief Executive Officer | 67 | 01-04-21 |
Kenzo Sawai
BRD | Director/Board Member | 55 | 01-04-21 |
Masatoshi Ohara
BRD | Director/Board Member | 73 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |